Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Biomedical Research Department, Diabetes and Obesity Research Division, Cedars-Sinai Medical Center, Los Angeles, California.
Am J Hypertens. 2018 Mar 10;31(4):394-401. doi: 10.1093/ajh/hpy013.
There are renal implications when employing intensive blood pressure control strategies. While this approach provides cardiovascular benefit in patients with and without chronic kidney disease, the impact on renal disease progression differs according to the pattern of underlying renal injury. In the setting of proteinuria, stringent blood pressure control has generally conferred a protective effect on renal disease progression, but in the absence of proteinuria, this benefit tends to be much less impressive. Thiazide diuretics are frequently part of the regimen to achieve intensive blood pressure control. These drugs can cause hyponatremia and present with biochemical evidence mimicking the syndrome of inappropriate antidiuretic hormone secretion. Altered prostaglandin transport may explain the unique susceptibility to this complication observed in some patients. Hyperkalemia is also a complication of intensive blood pressure lowering particularly in the setting of renin-angiotensin-aldosterone blockade. There are strategies and new drugs now available that can allow use of these blockers and at the same time ensure a normal plasma potassium concentration.
在采用强化血压控制策略时,可能会对肾脏产生影响。虽然这种方法对有和没有慢性肾脏病的患者都有心血管益处,但对肾脏疾病进展的影响因潜在肾脏损伤的模式而异。在蛋白尿的情况下,严格的血压控制通常对肾脏疾病的进展有保护作用,但在没有蛋白尿的情况下,这种益处往往不那么明显。噻嗪类利尿剂通常是实现强化血压控制方案的一部分。这些药物可引起低钠血症,并出现类似于抗利尿激素分泌不当综合征的生化证据。前列腺素转运的改变可能解释了一些患者中观察到的这种并发症的独特易感性。低钾血症也是强化降压的并发症,特别是在肾素-血管紧张素-醛固酮阻断的情况下。现在有一些策略和新药可以使用这些阻滞剂,同时确保正常的血浆钾浓度。